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Teaser: 
Safety driven differentiation of pharmaceuticals is gaining traction with the increasing number 
and complexity of new therapies.   
Abstract 
With increasing expectations to provide evidence of drugs efficacy, safety and cost-effectiveness, 
best-in-class drugs are a major value driver for the pharmaceutical industry. Superior safety is a 
key differentiation criterion that may be achieved through better risk/benefit profiles, safety 
margins, fewer contraindications and improved patient compliance. To accomplish this, 
comparative safety assessments using  innovative and adaptive non-clinical and clinical-outcome-
based approaches should be undertaken, and continuous strategic adjustments must be made as the 
risk/benefit profiles evolve. Key success criteria include scientific expertise and integration 
between all disciplines during the full extent of the drug development process. . 
 
Differentiation is a key value driver 
The competitive landscape of pharmaceuticals is more crowded than ever before. About 60% of a 
specific drug target in active pre-clinical and clinical phase are being pursued by more than one 
company, while the vast majority (88%) of validated targets (for which at least one drug is already 
approved) are being pursued by multiple companies [1]. In addition to fierce competition, drug 
development is also getting more challenging with increasing requirements from health authorities 
and mounting pressure from payers and pricing governance to demonstrate the unique value of 
each new drug. For these reasons there has been a lot of debate on how pharma can continue to 
thrive, and whether a first or best-in-class strategy will lead to success. An analysis by The Boston 
Consulting Group in 2013 suggests that the first-in-class drug candidates have a higher value than 
the best-in-class [2], while a follow-up analysis by McKinsey in 2014 showed that context makes 
a significant difference [3]. Yet another older analysis by Booth and Zemmel in 2003 [4] showed 
that first in class drugs have not created more value than their follow-on counterparts as they are 
able to differentiate themselves through improved drug development strategies.  
 
There is no doubt that a first-in-class drug can be of high value if there are no existing therapies 
for the disease it intends to treat. In this case, superiority in efficacy and safety over placebo are 
the only differentiation requirements. However, often there is a standard of care (SoC) available 
to which the test compounds has to show superiority in order to convince regulators and payers 
[5].  Furthermore, the value may also be hampered by high development costs for validating a 
novel target. On the other hand, follow-on drugs have the downside of limitations in the patent 
space and fierce competition in the market, but have the potential upside of an easier and less 
resource intensive development path as they can leverage knowledge of the predecessors. 
Moreover, the path to best-in-class can also boost innovation, leading to improved preclinical risk 
mitigation and quicker development times.  Thus a key value-driver in pharmaceutical industry is 
not solely whether the drug is potential first-in-class, but also how well the drug may be 
differentiated from existing therapies. In this review, we highlight the safety differentiation 
concept by providing examples from post marketing evidences and possible development 
approaches. While the intent with this review is not to describe drug development in breadth and 
depth, we hope to trigger future discussions and analysis on this topic by the pharmaceutical 
community.   
Safety driven differentiation  
The concept of differentiation through efficacy or convenience are well established in the clinical 
setting, but safety is also a key advantage for patients, and the need for safety driven differentiation 
is particularly gaining traction with the increasing number and complexity of new therapies. There 
are several historical examples where safety was the dominant driver for differentiation within the 
same drug class, comprising drugs with similar mechanism of action with or without similar 
chemical structure. A drastic example with major differences in safety is the thiazolidinedione 
class of compounds developed for treatment of type-2 diabetes. In spite of their common 
mechanism of action and closely related chemical structures, their receptor-binding affinities and 
consequently their unique safety profiles differ [6].  Troglitazone was withdrawn from the market 
due to hepatotoxicity, while rosiglitazone was withdrawn from some markets due to cardio- and 
cerebro-vascular events, and pioglitazone has been associated with increased incidences of bladder 
cancer although the causal relationship remains controversial [7]. While these thiazolidinediones 
have different serious adverse drug reactions (ADRs), no alternative emerged from this chemical 
class with a cleaner safety profile. However, this is not always the case as demonstrated by the 
structurally similar Cox-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), where the former 
was removed from the market due to cardiovascular risk, while the latter has been demonstrated 
to be safe in the same patient population [8,9]. The original intent to develop first-in-class selective 
Cox-2 inhibitors was their expected improved gastrointestinal and renal safety profile in 
comparison to non-selective Cox enzyme inhibitors. Indeed, a recent major safety comparison 
study of osteoarthritis and  rheumatoid arthritis patient populations has shown that Celebrex results 
in less gastrointestinal and renal safety liabilities as compared to the non-selective and structurally 
different Cox-2 inhibitor ibuprofen[10]. Another example of safety differentiation by chemical 
modifications are amiodarone (approved by the FDA in 1962) and its chemical derivative, 
dronedarone (approved in 2009), both developed for treatment of atrial fibrillation. While 
amiodarone is more efficacious and more toxic, dronedarone is less efficacious but safer and thus 
is used as a first-line therapy with the exception of patients with decompensated chronic heart 
failure, structural heart disease, permanent atrial fibrillation, and not receiving digoxin [11,12]. 
The improved safety of dronedarone is largely attributed to avoiding iodine moieties that are 
present in amiodarone and responsible for toxic effects on the thyroid gland, lung, liver and skin.  
Importantly however, dronedarone does not have a clean cardiac safety profile, as reflected by the 
narrow target patient population as described above [13]. Finally, an example of a minimal 
chemistry change for improved safety profile is the newly approved deutetrabenazine (Austedo) 
developed for treatment of Huntington’s chorea. In this case, the only change from the predecessor 
tetrabenazine (Xenazine) is the replacement of hydrogen to deuterium.The use of the “heavier 
hydrogen isotope”, deuterium, makes the chemical bond breaking during metabolism slower and 
thus provides a dosing advantage and improved safety profile [14]. Taken together, the examples 
demonstrate that first-in-class could carry the danger of unexpected adverse events, and that 
development of safer alternatives is not straight forward with regards to neither chemistry or target 
selection.  A drug class comprising the same mechanism of action, but with different or similar 
chemical structures, can result in large safety differentiation opportunities either in terms of 
different, or in mitigation of the same organ toxicities.  
 
While liver and heart are the most frequently reported target organs of drug-induced toxicities post 
marketing, the nervous system has shown to be particularly challenging as a target for development 
of efficacious and safe drugs [15-17]. In terms of safety differentiation challenges for drugs in 
neurology, the crux is often related to target specificity and/or to enable preferential delivery to 
either the peripheral or central nervous system (CNS) [18,19]. The first generation of anti-
histamine drugs acting on the H1 receptors are associated with several CNS side effects such as 
sedation, coordination issues, dizziness, inability to concentrate and paradoxical reactions in 
children and the elderly [20].  An important determinant of these effects is related to high level of 
CNS penetration, poor receptor selectivity, involving anti-muscarinic, anti-α-adrenergic, anti-
serotonin effects, as well as serotoninergic transmission [20,21].. However, by reducing their 
ability to cross the blood brain barrier (BBB), the second-generation anti-histamines are devoid of 
significant CNS side effects [20]. Another example are the tri-cyclic anti-depressants (tCAs) which 
have in general been replaced by the selective serotonine re-uptake receptor  inhibitors (SSRIs) as 
first-line treatment for depression due to improved safety profile[22]. While both of these drug 
classes must pass the BBB to act on their respective therapeutical targets, the tCAs bind additional 
targets affecting sodium, cholinergic, adrenergic and histamine signaling which are associated with 
their serious adverse effects and narrow safety margin in overdose and require titration upon start 
of treatment situation [22]. However, the benefit-risk depends on the indication it intends to treat, 
and tCAs are for instance often considered as first-line treatment for neuropathic pain due to 
additional pain-modulating effects and lack of better alternatives [23]. The crucial question is 
whether it is possible to develop effective drugs for treatment of chronic neuropathic pain that are 
devoid of CNS side effects such as sedation and addiction, thereby also curbing the opioid crisis.  
Indeed, there are recent advances with the discovery of so-called “biased-agonists” of micro opioid 
receptor (MOR) that lack side-effects such as constipation and respiratory depression as 
demonstrated in mice [24], however,  these may not necessarily prevent abuse potential. On the 
other hand, a novel opioid, BU08028 (University of Bath) which shows a similar binding profile 
to MOR as buprenorphine, but with improved efficacy at the nociceptin opioid peptide (NOP) 
receptor which blocks addictive effects, has shown a promising non-clinical development with 
lack of abuse potential in non-human primates  [25]. Finally, but importantly, recent research has 
also demonstrated that the peripheral nervous system might play a much more important role in 
pain sensation than previously thought, thereby opening the door for development of new 
peripherally acting therapeutics devoid of CNS side effects [26-28]. While many of the novel 
targets for human analgesic intervention remain hypothetical, they fuel the pharmaceutical pipeline 
with alternative therapeutical options which require, as seen with the above examples, – thorough 
pharmacodynamics and pharmacokinetic evaluation for balanced efficacy and safety. 
 
Other examples of safety differentiation opportunities is the importance of understanding drug-
drug interactions (DDI), vulnerable patient populations, as well as co-morbidities of SoC side 
effects and disease. The risk for DDI may be higher in geriatrics due to a larger number of 
medications, and critically ill patients in intensive care units due to complexity of pharmacotherapy 
combined with disease severity [29]. With regards to potential co-morbidities of SoC side effects 
and disease, rheumatoid arthritis (RA) may serve as an important example. RA is associated with 
increased risk of infections, cardiovascular events, and gastro-intestinal ulcers and cancer [30], 
and many of the current therapies for RA have safety liabilities that may exacerbate these 
complications [31]. For instance, the disease modifying therapies comprising biologics (currently 
mostly anti-TNF administered intravenously) increase the risk of severe infections due to 
immunosuppression that can persist long after treatment has been stopped. Glucocorticoids are 
associated with increased blood pressure, elevated cholesterol levels, and hyperglycemia, while 
the non-steroidal anti-inflammatory drugs have an increased risk of gastro-intestinal ulcers and 
cardiovascular risk. Hence, there is an overlap between some of the co-morbidities and the 
therapies which can be challenging when evaluating the risk-benefit ratio. There are, however, 
several exciting opportunities in the field of RA. The subcutaneously administered IL-6 antibody, 
sarilumab, developed by Sanofi/Regeneron and approved for RA in 2017, may offer advantages 
to the SoC although some side effects of immunosuppression have been shown [32]. The oral small 
molecule JAK-3 inhibitor, tofacitinib, developed for RA by Pfizer and approved in 2012, also 
shows immunosuppressive effects [33]. However, it has a significant advantage in the clinical 
management of RA as the immune-system recovers more rapidly after stopping the treatment as 
compared to the intravenously or subcutaneously administered biologic, anti-TNF-alpha.  Thus, 
not surprisingly, further oral JAK inhibitors are currently in development [34]. The JAK1-2 
inhibitor, baricitinib, developed by Incyte/Eli Lilly, has received approval in Europe while pending 
in U.S. The JAK-1 inhibitors, filgotinib developed by Galapagos, and upadacitinib developed by 
AbbVie, as well as the JAK-3 inhibitor, peficitinib, developed by Astellas, are also in clinical 
phase 3 development. Thus, safer therapeutic alternatives, with hopefully less co-morbidities, are 
on the horizon for RA.  
 
 
 
Drug development approaches 
The first challenge in a drug development program is to identify relevant therapeutic targets, which 
requires a thorough understanding of the molecular pathways of the disease and the target’s 
relevance tohuman physiology and safety. As a start, a hypothesis of the target’s role in 
pharmacological and safety is created. Thereafter, a target validation process ensues where benefit 
and limitations in safety and efficacy are explored and compared to other target alternatives. To 
this end, access to human tissue, stem cell biology, genome editing and phenotypic screening are 
some of the many crucial elements. However, pharmacovigilance of drugs developed for the same 
target or indication is also key, in order to guide target selection and safety differentiation testing 
strategies. 
Great progress has been made in the ever-growing portfolio of different modalities as well as novel 
approaches in drug delivery systems. Perhaps especially noteworthy are the few gene therapies 
that have recently successfully completed pivotal trials without major safety concerns  [35]. For 
gene therapies using viral delivery, the route of administration (systemic versus local) and the 
tissue selectivity (tropism of the capsid) are often more important for safety, as opposed to potential 
genotoxicity or immunogenicity which are rare [36,37]. The CAR-T cell therapy methods, where 
the patient’s own T cells are genetically engineered to target cancer cells are also emerging, 
currently consisting of the CD19-directed CAR-T cell therapy Kymriah (Novartis) for B-cell acute 
lymphoblastic leukemia and non-Hodgkin lymphoma, and Yescarta (Kite Pharma/Gilead Sciences) 
for treatment of B cell lymphomas [38]. Expansion of this technology into other cancers is awaited 
provided safety challenges such as “on-target off-tumor activity” and incidences of cytokine 
release syndrome can be mitigated [39,40]. Antibody therapeutics can have superior safety 
compared to small molecules due to their high selectivity, low off-target binding and lack of 
intrinsic biochemical toxicity. However, the disadvantage is that the route of administration 
generally has to be parenteral instead of oral due to low stability of proteins in the stomach, low 
absorption in the intestines, as well as limitations in reaching intracellular targets. Consequently, 
biologics may require parenteral administration, which may also confer safety risks (i.e infections) 
as well as inconveniencies and thus patient compliance issues. In contrast, LMW show superiority 
in terms of amenability for oral delivery, potential broad tissue distribution and access to 
intracellular targets. Therefore, LMW may be the preferred modality in spite of their potential 
downside of risk for off-target binding or generation of toxic metabolites. A recent successful 
example is Amicus’ oral LMW, migalastat, (approved 2016) for treatment of Fabry disease which 
is deemed easier to tolerate and to have fewer side effects than the preceding marketed enzyme 
replacement therapies given intravenously [41,42]. Fabry disease is a form of lysosomal storage 
disease caused by mutations in α-galactosidase A (α-GalA), an enzyme that is important for 
processing sphingolipids and whose dysfunction leads to systemic vasculopathy among other 
morbidities [42]. Interestingly, the LMW, migalastat, works as a pharmacological chaperone by 
binding to faulty α-GalA, thereby shifting its folding towards proper conformation.  Recent 
advances in improving delivery of biologics have, however, also been made by i.e improvement 
of protein-engineering and delivery systems that enhance protein stability and absorption have 
however made progress [43].  Tiziana Life Sciences’ oral anti-CD3 antibody, which is in clinical 
Ph2a for non-alcoholic steatohepatitis (NASH), stands out as a unique example in the crowd of 
small molecules that are pursued for the same indication [44]. Should it work, it would not only 
be a breakthrough for treating the disease, but also a game changer for oral antibody treatment of 
diseases in general. Breakthroughs in delivery of biologics across the BBB have also been achieved 
by use of a “molecular Trojan horse technology”, in which the biologics are fused to a mAb which 
binds to an endogenous BBB transporter and thereby acts  as a Trojan horse to deliver the 
biological pharmaceutical across the barrier [45]. Finally, but noteworthy is also the progress made 
in pulmonary drug delivery. While the advantage for respiratory drugs is the direct delivery to the 
target, pulmonary delivery can also have benefits over oral delivery for treatment of systemic 
diseases as i.e first-pass metabolism is avoided and potentially fewer side effects may be achieved 
[46,47].  
The first line of safety assessments may start during the lead optimization phase. These 
assessments comprise in vitro-based evaluations of absorption, distribution, metabolism and 
excretion (ADME), pharmacokinetic (PK), selectivity and off-target pharmacological assays for 
small molecules, and in silico tools of structural alerts. These assays require small amounts of 
compound and are relatively fast and inexpensive, thus excellent for direct comparison of 
competitive contenders. The tools are also evolving and updated based on real world evidence, as 
perhaps particularly well illustrated for the off-target pharmacology assays [48,49]. For example 
the development of the second generation anti-histamine, terfenadine was discovered to cause 
cardiac arrhythmias due to hERG inhibition, while its structurally related major metabolite 
fexofenadine (Allegra) did not show this off-target effect [50]. This, among other examples, 
subsequently triggered the development of preclinical secondary pharmacology profiling for off-
targets associated with serious ADRs such as ventricular arrhythmias [49,51], as also recognized 
by the US Food and Drug Administration (FDA) [52]. Today, secondary pharmacology profiling 
is routinely performed by pharmaceutical companies in the early development phase, generally 
consisting of an initial smaller panel followed by a full panel of up to 60 targets comprising G-
protein-coupled receptors (GPCRs), kinases, proteases, nuclear receptors, enzymes, ion channels 
and transporters [48,53]. To this end, an understanding of the predictive power and the usefulness 
of the assays is critical, as is their continuous validation by the pharmaceutical community [54,55].    
Based on the accumulated data from the in initial vitro-based evaluations, in silico tools to assess 
quantitative structure activity relationship (QSAR) may be developed to speed up the de-selection 
or refinement of compounds. An example for use of QSAR is the development of ranitidine 
(approved in 1981), a histamine H2 receptor antagonist for decreasing stomach acid production. 
By help of QSAR modeling, the imidazole ring of the predecessor cimetidine  (approved 1976) 
was modified and a better safety profile and higher efficacy were achieved for ranitidine [56,57]. 
Steroselectivity of molecules is also an important consideration, as production of a single 
enantiomer may have the advantage of enabling lower dose, simpler dose-response relationship 
and lower toxicity [58]. However, creating a single enantiomer is not always straight forward as 
demonstrated for thalidomide, a drug that was introduced in 1957 as a sedative and anti-nausea 
agent but withdrawn from the market due to teratogenicity. As thalidomide consists of a racemic 
mixture, attempts to develop a single enantiomer were made in the hope that it might remove its 
teratogenic risk. However, this was shown to be difficult due to chiral inter-conversion [58]. 
Stabilization of the chiral center with deuterium has however been achieved for a thalidomide 
analogue (CC-122), which is currently in clinical phase 1 and 2 development by Celgene for 
various cancers [59]. While it’s unknown whether stereoselectivity could reduce the teratogenicity 
risk, there may however be new opportunities for thalidomide on the horizon, as a mechanistic link 
(degradation of SALL4) to its teratogenicity was recently discovered [60]. Another element during 
the optimization phase includes considerations to develop pro-drugs for enhancing drug delivery, 
pharmacokinetics, decrease toxicity, or to target the drug to specific cells or tissues [61]. With 
regards to the latter,  pro-drugs that depend on cytochrome P450 systems for activation have shown 
to be a versatile approach for targeting drug activation to the liver, tumors or to hypoxic tissues 
[61]. In the case where CNS-effects are to be avoided then structural modification to limit brain 
concentrations may also be pursued [18]. Improvement of metabolic stability and prediction of 
human major, specific or potentially toxic metabolites are also important components of the 
optimization phase [62]. Human in vivo ADME studies are typically conducted during the later 
phases (phase 2-3) of clinical development, and identification of metabolites not adequately 
evaluated for safety in the preclinical toxicology program could be a costly surprise. In this case, 
alternative pre-clinical species may be needed for further evaluation, and in worst-case put the 
development program to a halt. Finally, but importantly, a crucial element of the optimization 
phase is to translate the identified safety hazards into human safety risk in correlation with the  
predicted exposure [63].  In absence of clinical data, PK information obtained from animal models 
is essential. However, use of exploratory clinical trials / P0 trials for obtaining a better insight into 
PK and ADME properties may also be considered. Moreover, while prediction of clinical 
therapeutic index (or safety margin) should be performed at early stage, it needs to be continuously 
re-adjusted as new in vitro and in vivo data emerge and put into context of the benefit-risk 
evaluation of the intended indication [63]. 
Exploratory sophisticated in vitro tools may also provide additional guidance for mechanistic 
insights of toxicities. Particularly noteworthy are the achievements in human stem cells. Using the 
inducible pluripotent stem cell technology, large quantities of any human specialized cell type may 
be generated from a patient’s skin sample, thereby opening many avenues for new drug testing 
strategies. For instance, safety and efficacy in the context of human genetic diversity and disease-
relevant genes may be explored, also opening opportunities for personalized medicine. Moreover, 
combined with the recent progress in microphysiological systems (MPS), enhanced preclinical to 
clinical translation may be achieved [64]. Use of MPS can also enable improved culture longevity 
which is key for assessing chronic toxicities, where exposures of low abundance metabolites over 
longer time, as well as adaptive changes may play a role. Although their use for safety prediction 
may be debated, anchorage to in vivo data can provide confidence. For instance, cross-species 
comparison using in vitro gut organoids from rat, dog and human enabled progression of a 
bromodomain-containing protein 4 (BRD4) inhibitor (AZD5153 by AstraZeneca) by 
demonstrating that gastrointestinal (GI) toxicity in dogs was not relevant to human. Translation of 
these data to the clinic was supported by using OTX015, a competitor compound developed by 
Merck, which is known to result in GI toxicity in rats but not in humans [65,66]. Alongside with 
the routine in vivo toxicology studies, in vivo head-to-head comparison of competitor compounds 
can be considered. However, an ethical consideration to reduce the use of animals is imperative, 
and must be evaluated in relation to the potential clinical safety gained.  Noteworthy though, 
comparative assessments using short duration in vivo studies and/or humanized animal models 
with improved translatability to human may help to reduce the drug development attrition rate, 
thereby also reducing the overall animal use.  
Lack of direct clinical trial comparisons of drugs makes it difficult to contrast medications 
according to efficacy and safety. Indirect comparisons may be performed, but are often challenging 
as trials may differ in design. The types of outcome measures have also changed over time, recently 
also including health related quality of life (HRQoL) and patient assessments of satisfaction.  
Comparisons may also be further complicated when combination treatments are used, i.e. for the 
purpose of obtaining additive beneficial effects and/or to lower the dosing regimens for avoiding 
side effects. Thus, direct head-to-head clinical trials may be essential for truly differentiating 
comparators. However, traditional randomized clinical trials (RCTs) following specific protocols 
with pre-specified treatment arms for a fixed period of time are time-consuming. Accordingly, 
innovative adaptive clinical trial designs that provide flexibility to adjust trial characteristics based 
on interim safety and efficacy results, are becoming increasingly popular[67]. For example 
modifications of the trial hypothesis, dose, investigational drug, cocktail of drugs, patient sample 
size or patient selection criteria, end points and exploratory biomarkers  may be made as the trial 
evolves [68]. By tailoring treatments based on interim clinical readouts and using breakthrough 
technological innovations, timelines are accelerated and the probability of success is improved. 
Integrated research platforms with a single master protocol  may be used, enabling testing of 
multiple drugs compared to a common placebo group, but also collaborations across academia and 
industry  [69]. A particularly successful example are the I-Spy 1-2 trials that tested a range of drugs 
for breast cancer and delivered six drug candidates for further testing in clinical phase 3 in record 
time [70]. By using adaptive trial design, the time required to identify the most effective drug 
candidates for different tumor subtypes were achieved. Other examples include adaptive trials run 
by the Global Alzheimer’s Platform (GAP) and the European Prevention of Alzheimer’s Dementia 
(EPAD) consortium[71].  Adaptive trials may i.e include interim analyses on whether the treatment 
slows cognitive decline, and the possibility to adapt the treatments based on biomarker readouts 
such as lowering Aβ for an anti-amyloid drug or lowering tau for a tau-based drug. Adaptive 
clinical trial designs are also actively explored by industry in their efforts to develop treatments 
for NASH, an indication that may require a cocktail of drugs and thus a series of combinatory 
evaluations [72]. Although adaptive trials are not new, they are not yet widely used, and are mostly 
referenced in the context of efficacy rather than safety. To this end it should however be noted that 
efficacy can also be directly related to safety, as noncompliance or inability to push a drug to fully 
efficacious dose can be to due suboptimal safety profiles. Moreover, adaptive trials do provide a 
broad potential for exploration of  safety differentiation. For example, head-to-head comparator 
trials may be adapted based on adverse event rates, patient withdrawal rates, discontinuation of 
therapy, need for intervention etc. Additionaly, individualized risk assessments that rely on patient-
specific factors as well as disease-drug interactions may also be explored . To this end, significant 
efforts are ongoing to develop improved predictive safety-biomarkers [73], companion safety-
diagnostics [74], and pharmacogenetic readouts for patient safety [75], which has also been 
recognized by the health authorities [76]. Thus, it is not unconceivable that genetic testing will be 
an important future tool for personalized safety, and consequently fundamental to differentiations 
strategies.   
  
Once large amounts of clinical data become available, additional non-clinical studies may be 
incorrectly perceived by lay audiences to be of limited value.  This perception may derive from 
the fact that many of the unexpected drug-induced toxicities in humans have not shown clear 
predictive signals during preclinical development, so why should further pre-clinical assessments 
help [77] ?. However, the inability of precise prediction of human toxicity is not necessarily due 
to lack of human-relevant models. In fact, analysis of concordance between preclinical and clinical 
safety observations has demonstrated high predictive power [78]. It is rather the issue that lack of 
preclinical findings does not necessarily imply a lower risk to humans. This is because it is simply 
impossible to test for all imaginable risk scenarios related to individual susceptibilities.  Once 
clinical data is available, however, the establishment of tailor-made models that recapitulate the 
findings observed in humans can be made. Such knowledge-driven refinement of non-clinical 
models provides a valuable strategy for retrospective analysis of toxicity mechanisms, and can 
also be effectively used to enhance the predictive value of preclinical safety assessments going 
forward. It is to this end that the use of non-clinical models may provide a great opportunity for 
gaining competitive advantage in contrast to large, lengthy, expensive and difficult to fully 
controlled clinical studies. For example, non-clinical studies can offer greater flexibility, the ability 
to control variables and thereby eliminate potential confounding factors. This can facilitate the 
demonstration of toxic mechanisms, guide the design of targeted clinical trials, or influence the 
drug label or practice of healthcare professionals. Such impact can, however, only be achieved if 
the translatability of the non-clinical model is validated by clinical data. Thus, to develop useful 
non-clinical models, meticulous prospective and retrospective clinical data collection of the 
affected individuals needs to be performed.  This practice of “reverse translation” is not an easy 
endeavor as it requires performing impromptu additional sample collections and ex vivo laboratory 
investigations, requiring available expertise and resources. While all of this may seem to involve 
formidable efforts, it is the scientifically correct way forward for improving the predictability of 
non-clinical models, which in turn will lead to the development of safer drugs. 
 
While science governs the drug development process, identification of a well differentiated value 
proposition and implementation of a commercial strategy is also imperative. To facilitate this 
integration, many drug developers use a key strategic document named the target product profile 
(TPP), a concept initially introduced by FDA. Its content is structured according to the labeling 
concept and includes a summary on i.e product characteristics, indication and use, non-clinical and 
clinical development results and plans. However, it also describes key safety and efficacy features 
as well as competitive positioning, which helps in identifying the key value proposition. To this 
end, alignment with market access strategies, including information on key stakeholders e.g. 
regulatory bodies and payers, target populations, product prescription strategy and patient use are 
crucial. Lastly, but importantly, a concerted dialogue between R&D and market access expertise 
is key and should be initiated in the early phases of drug development, helping to guide the 
researchers to take the best choices among the various possible safety differentiation opportunities 
(Figure 1). 
Key to success  
Successful drugs will be those that demonstrate their value to all stakeholders and do so early in 
development. Patients, physicians and payers must be convinced that the new drug provides 
improvement in quality of lives and reduces socio-economic burdens associated with disease or 
co-morbidities as compared to existing therapies. In a changing environment of increasing 
competition, it is also possible that the patient perspectives of safety and tolerability may have 
influence on payers, and thus on how a product penetrates the marketplace. Thus, the drug 
development focus must go beyond efficacy and include a holistic assessment of patient-outcomes 
where patient safety is much more than just minimizing side-effects. Improved safety may include 
mitigation of side effects, more efficacious doses, longer therapeutic duration, broader co-
treatment opportunities, fewer contraindications, treatment of high risk patient groups such as 
pregnant women, children, geriatric patients, or poly-morbid patients, as well as a safer and more 
convenient treatment regimens leading to improved patient compliance. 
 
An organizational structure where scientific expertise is combined with efficient business-driven 
decisions is essential. Safety assessment is a holistic approach starting at the early phase of drug 
discovery to aid the selection of molecules that show disease relevant efficacy at the desired 
exposure. Although ADME and PK methods are available in the early phase and can be applied 
effectively, safety assessment often starts relatively late and this gap should be closed. 
Comparative safety assessment needs to be an integrated exercise by all key disciplinary experts 
during the full extent of the drug development and the pre-clinical and clinical interface should be 
strengthened. Disciplines need to cooperate and integrate knowledge in order to enable risk-benefit 
decision-making. This assessment needs to start at the beginning of any drug discovery project, 
and continuously be adjusted during the development as new information from internal and 
competitor data emerge [79,80]. Approaches may include use of innovative non-clinical models 
with improved translation to humans, adding readouts outside the standard guidelines and/or 
optimizing clinical trial designs [68,81]. Post-marketing pharmacovigilance will likely also 
become increasingly important, not only for regulatory obligations, but also for competitive safety 
differentiation opportunities [9,82]. In fact, companies may already have an advantage in their 
marketed therapies that could be exploited, or it may contribute to shape the development of their 
follow-on drugs. Importantly, these opportunities may not only fuel pharmaceutical development, 
but ultimately provide safer drugs and thus improve patient care.  
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